
Insulin Therapy and GLP-1 analogues



Dr. Spurgeon
Dept of Endocrinology,
Christian Medical College, Vellore

Progressive Beta Cell failure in Type II Diabetes Mellitus



What are the anabolic effects of Insulin?

- -Stimulates entry of amino acids into cells, enhancing protein synthesis
- Enhances fat storage (lipogenesis) and prevents mobilization of fat for energy (Lipolysis and Ketogenesis)
- -Stimulates entry of glucose into cells for utilization as energy source
- Promotes storage of glucose as glycogen in muscle and liver cells (glycogenesis)

"The Magnificent Seven"

1. Type 2 diabetes not controlled with maximal doses of Oral Hypoglycaemic agents

What do you mean by maximal doses of OHAs?

Metformin 2500/3000mg a day

+

Glipizide 20mg/glibenclemide15-20mg/day Gliciazide 320mg/ Glimepride 6-8mg/day

+

Rosiglitazone 8mg/Pioglitazone 45mg/day

2. Type 2 diabetes during periods of physiological stress (surgery, infection)

Continue OHAs simultaneously.

Stop metformin in case of severe infections or impending reduction in renal perfusion

3. Pregestational diabetes

Metformin may be continued

Discontinue other medications

4. Use of parenteral nutrition or high-caloric supplements

5. Diabetic ketoacidosis (DKA)/Hyperosmolar hyperglycemic nonketotic syndrome (HHNS)

6. Progressive complications: proliferative retinopathy/maculopathy, progressive or painful neuropathy

For rapid control and tighter adjustment

7. Chronic Renal Failure

For all above a creatinine of 4.0mg/dl

Cutoffs for other OHAs:-


Metformin: 1.5mg/dl

Glimeperide/Glibenclemide: 2.0mg/dl

Glipizide: 2.5mg/dl

Pioglitazone/Rosiglitazone: 4.0mg/dl

What is the normal insulin secretory pattern?



How does one classify the types of insulin?

- ♦ Generally classified according to peak effect and duration of action
- ♦ Short acting: regular/ Lispro /Aspart
- **♦ Intermediate acting: NPH/ Lente**
- ◆ Premixed:(30/70), (50/50)

What are the types of Insulin?

Short acting

Intermediate acting

Long acting

Analogs

Short acting: Lispro, Aspart

Long acting: Glargine


: Regular insulin

: Lente insulin

NPH insulin

: Ultralente


What is the time action profile of different types of insulins?



What are the types of insulin regimens?

- Premixed regimen
- Split mix regimen
- Basal bolus regime (multidose)
- Bedtime dosing alone (NPH/Lente/Glargine)
- Infusion

Premixed insulin:action



Premixed insulin

Premixed(30/70): Regular: 30 % NPH:
 70%

 Premixed (50/50): Regular 50% NPH 50%

Premixed Analogs
 Biphasic insulin aspart (30/70)

30% : Aspart

70%: protaminated aspart

Insulin Therapy Regimens

♦ Usual starting dose: 0.5-1.0 unit/kg/day

Premixed insulin

- Dose adjustment:
- The fasting sugar depends on the night dose of insulin
- The post breakfast sugar depends on the morning dose of insulin
- Rough calculation increase the insulin by one unit to reduce the sugars by 25mg/dl

Self Monitoring is crucial

Glucometers At least 6-8 times a week ideally



Premixed insulin

Advantages

- more accurate dosing
- lesser injections
- Pen devices administer premixed forms

Disadvantages


- Fine tuning may not be possible
- Strict meal pattern
- Nocturnal hypoglycemia
- May need "diet changes for insulin" rather than "insulin changes for diet"

Split-mixed insulin

Common combinations:
 Short acting plus intermediate acting in a syringe:


Regular + NPH

How to adjust insulin doses in a split mix




Increase regular insulin

How to adjust insulin doses in a split mix




Reduce regular insulin

How to adjust insulin doses in a split mix?



Increase NPH insulin

How to adjust insulin doses in a split mix?



Split-mixed insulin

Advantages

- Less hypoglycaemia, with fine tuning
- More physiologic
- Adjustable meal pattern

Disadvantages

- More patient education required
- Cumbersome mixing
- Pen device not feasible if two injections are planned for.

Bedtime NPH/Glargine

Continue daytime oral hypoglycaemic agents:
especially sulphonylureas
(The BIDS regimen)

Advantage: Once daily dosing Easy dose titration

Disadvantage: May need premeal bolus

NPH



Glargine

Glargine

Bedtime Long- acting

Advantages


Single Daily dosing

Disadvantages

Suitable for only <15% of

Type 2 Diabetes

Basal bolus regime(multidose)



Starting insulin in type 2 diabetes - patient on full dose OHA

- Continue the OHA
- Start on insulin (approx 0.2 U/kg/day,morning 2/3, evening 1/3)
- Reassess control with SMBG & titrate dosage
- Consider adding short acting premeal bolus if uncontrolled PPBG
- Consider withdrawing sulphonylurea

Can Oral hypoglycaemic agents be continued at the same time with insulin?

Metformin

Best continued if renal function is normal. May reduce insulin requirements by 15-30%.

- Adjunctive weight reducing effect
- Thiazolidinediones
- May be continued with insulin.
- Can reduce insulin requirements from 15-60%
- Major issue of weight gain, accentuated by insulin: 7.5%. 15%>5kg.

Can Oral hypoglycaemic agents be continued at the same time with insulin?

Sulphonylureas

- Glimeperide: doses of 2-4mg a day have a peripheral GLUT-4 activity reducing insulin requirement by 10-20%.
- Glipizide and Glibenclemide can reduce insulin requirements by 5-15%.
- Unpredictable- recommended previously in those with high C-peptide levels

Infusion

Used in situations like DKA, immediate control of sugars

monitor sugars more frequently monitor potassium over lap with long acting insulin

GLP-1 Analogues

- accounted for by following effects:
- stimulation of insulin secretion
- inhibition of glucagon release
- delay of gastric emptying
- increase of insulin sensitivity

- Stimulates insulin gene expression
- Stimulates insulin biosynthesis
- Stimulates -cell proliferation and survival
- Stimulates differentiation of exocrine cells or islet
- precusors toward -cell phenotype

When do you start?

- As mono or combination therapy
- Obese type 2 Diabetics
- Along with oral drugs.

Development of Exenatide: An Incretin Mimetic

- Exenatide (Exendin-4)
- Synthetic version of salivary protein
- found in the Gila monster
- Approximately 50% identity with
- human GLP-1
- Binds to known human GLP-1
- receptors on cells in vitro
- Resistant to DPP-IV inactivation

DOSAGE AND ADMINISTRATION

- Inject subcutaneously within 60 minutes prior to morning and evening meals (or before the two main meals of the day, approximately 6 hours or more apart.
- Initiate at 5 mcg per dose twice daily; increase to 10 mcg twice daily after 1 month based on clinical response.
- Initiation with 5 mcg reduces the incidence and severity of gastrointestinal side effects.

- BYETTA is supplied as 250 mcg/mL exenatide in:
- 5 mcg per dose, 60 doses, 1.2 mL prefilled pen
- 10 mcg per dose, 60 doses, 2.4 mL prefilled pen

Contraindicated---

- Type 1 DM
- History of pancreatic disease
- Should not be used in patients with severe renal impairment (creatinine clearance < 30 mL/min).
- Severe GI problems
- Hypersenitivity to drug

Summarizing.....

Insulin administration is suitably as premixed fashion for most type 2 diabetes. Split-mix may be required in a subset.

The neccessity of self blood glucose monitoring as a accessory is emphasized.